Patents Assigned to Biotie Therapies, Inc.
-
Publication number: 20220088024Abstract: Provided herein are methods and compositions for treatment of patients with cancer using tozadenant. Methods include monotherapy as well as combination therapy.Type: ApplicationFiled: December 19, 2019Publication date: March 24, 2022Applicant: Biotie Therapies, Inc.Inventor: Cory Kostrub
-
Patent number: 10973784Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.Type: GrantFiled: January 16, 2019Date of Patent: April 13, 2021Assignee: Biotie Therapies, Inc.Inventors: Christopher G. Salentine, Thomas R. Malefyt
-
Patent number: 10653699Abstract: The present invention provides a controlled-release composition containing tozadenant, at least one cellulose ether, and one or more pharmaceutically acceptable excipients. In the composition, the tozadenant is present in an amount ranging from about 30% (w/w) to about 65% (w/w) based on the total composition weight; and the cellulose ether is present in an amount sufficient to provide: not less than about 10% and not more than about 30% tozadenant dissolution over a 2-hour test period, not less than about 55% tozadenant dissolution over a 10-hour test period, and not less than about 80% tozadenant dissolution over a 16-hour test period. Use of the composition for treatment of Parkinson's disease is also described.Type: GrantFiled: May 23, 2016Date of Patent: May 19, 2020Assignee: Biotie Therapies, Inc.Inventors: Thomas R. Malefyt, Christopher G. Salentine, Mehdi Paborji, Stephen I. Bandak
-
Patent number: 10561638Abstract: Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.Type: GrantFiled: December 6, 2013Date of Patent: February 18, 2020Assignee: Biotie Therapies, Inc.Inventors: Tom Woiwode, Mark Moran, Lesley Pickford
-
Patent number: 10314798Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.Type: GrantFiled: September 29, 2017Date of Patent: June 11, 2019Assignee: Biotie Therapies, Inc.Inventors: Christopher G. Salentine, Thomas R. Malefyt
-
Publication number: 20180303843Abstract: The present invention provides a controlled-release composition containing tozadenant, at least one cellulose ether, and one or more pharmaceutically acceptable excipients. In the composition, the tozadenant is present in an amount ranging from about 30% (w/w) to about 65% (w/w) based on the total composition weight; and the cellulose ether is present in an amount sufficient to provide: not less than about 10% and not more than about 30% tozadenant dissolution over a 2-hour test period, not less than about 55% tozadenant dissolution over a 10-hour test period, and not less than about 80% tozadenant dissolution over a 16-hour test period. Use of the composition for treatment of Parkinson's disease is also described.Type: ApplicationFiled: May 23, 2016Publication date: October 25, 2018Applicant: Biotie Therapies, Inc.Inventor: Thomas R. MALEFYT
-
Publication number: 20180092868Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.Type: ApplicationFiled: September 29, 2017Publication date: April 5, 2018Applicant: Biotie Therapies, Inc.Inventors: Christopher G. SALENTINE, Thomas R. MALEFYT
-
Patent number: 8735576Abstract: Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance.Type: GrantFiled: August 5, 2013Date of Patent: May 27, 2014Assignee: Biotie Therapies, Inc.Inventors: Thomas R. Malefyt, Lesley Pickford
-
Publication number: 20140099336Abstract: Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.Type: ApplicationFiled: December 6, 2013Publication date: April 10, 2014Applicant: Biotie Therapies, Inc.Inventors: Tom Woiwode, Mark Moran, Lesley Pickford
-
Publication number: 20130317019Abstract: Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinson's disease by administering an effective amount of an Adenosine 2a antagonist.Type: ApplicationFiled: November 4, 2011Publication date: November 28, 2013Applicant: BIOTIE THERAPIES, INC.Inventors: Stephen I. Bandak, Kevin J. Black, Meghan C. Campbell
-
Publication number: 20130317219Abstract: Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: Biotie Therapies, Inc.Inventors: Thomas R. Malefyt, Lesley Pickford
-
Patent number: 8501938Abstract: Provided are compounds of formula I or II that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods oftreating patients suffering from or susceptible to at least one symptom of abuse of dependence on, or withdrawal from at least one substance.Type: GrantFiled: June 16, 2010Date of Patent: August 6, 2013Assignee: Biotie Therapies, Inc.Inventors: Thomas R. Malefyt, Leslie Pickford
-
Patent number: 8212044Abstract: Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance.Type: GrantFiled: November 17, 2011Date of Patent: July 3, 2012Assignee: Biotie Therapies, Inc.Inventors: Thomas R. Malefyt, Lesley Pickford
-
Patent number: 8168785Abstract: Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance.Type: GrantFiled: June 17, 2009Date of Patent: May 1, 2012Assignee: Biotie Therapies, Inc.Inventors: Thomas R. Malefyt, Lesley Pickford
-
Publication number: 20120083604Abstract: Provided are compounds of formula I or II that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods oftreating patients suffering from or susceptible to at least one symptom of abuse of dependence on, or withdrawal from at least one substance.Type: ApplicationFiled: June 16, 2010Publication date: April 5, 2012Applicant: BIOTIE THERAPIES, INC.Inventors: Thomas R. Malefyt, Leslie Pickford
-
Publication number: 20120065403Abstract: Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: BIOTIE THERAPIES, INC.Inventors: Thomas R. Malefyt, Lesley Pickford